or Try an Advanced Search...

    Technical Analysis for VIRX - Viracta Therapeutics, Inc.

    Grade Last Price % Change Price Change
    F 0.51 -6.20% -0.03
    VIRX closed down 6.2 percent on Monday, July 1, 2024, on 1.57 times normal volume. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- so don't be surprised if it goes sideways or bounces.
    0 Watchers
    Watchlist Portfolio

    Trend Table & Recent EOD Trading Signals

    ADX Long Term Intermediate Term Short Term
    Weak or Absent Down Down Down
    Historical VIRX trend table...
    Date Alert Name Type % Chg
    MACD Bearish Signal Line Cross Bearish 0.00%
    Wide Bands Range Expansion 0.00%
    Oversold Stochastic Weakness 0.00%
    Outside Day Range Expansion -6.20%
    Wide Bands Range Expansion -6.20%
    Oversold Stochastic Weakness -6.20%
    NR7 Range Contraction -11.76%
    Narrow Range Bar Range Contraction -11.76%
    Wide Bands Range Expansion -11.76%
    Oversold Stochastic Weakness -11.76%
    Older End-of-Day Signals for VIRX ...

       Recent Intraday Alerts

    Alert Time
    Fell Below Previous Day's Low about 10 hours ago
    Down 2 % about 10 hours ago
    Down 1% about 10 hours ago
    Up 2% about 10 hours ago
    Up 1% about 10 hours ago
    View Earlier Intraday Alerts

    Get this analysis on your stocks daily!

    Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
    Track My Stocks
    Configure default chart indicators
    VIRX Chart by TradingView
    Basic chart:

    Profile

    Viracta Therapeutics, Inc., a precision oncology company, engages in developing drugs for the treatment of virus-associated malignancies. It is developing nanatinostat, an oral combination therapy in combination with the antiviral agent valganciclovir that is in Phase II clinical trial for Epstein-Barr virus-positive lymphoma. The company was founded in 2007 and is headquartered in Cardiff, California.
    Classification
    Sector: Healthcare
    Industry: Biotechnology
    Keywords: Cancer Lymphoma Hematology Antiviral Drug Anatomical Pathology

    Is VIRX a Buy, Sell or Hold?

    Indicator Bull Case Neutral / Hold Bear Case
    50 DMA
    200 DMA
    ADX Trend
    Oversold / Overbought
    Relative Strength
    Counts: 0 bullish, 3 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.

    Recent News

    Date Title
    May 17 Viracta Therapeutics Announces New Employment Inducement Grants
    May 14 Viracta Therapeutics appoints Michael Faerm as CFO
    May 14 Viracta Therapeutics Appoints Michael Faerm as Chief Financial Officer
    May 7 Viracta Therapeutics to Present at the RBC Capital Markets Global Healthcare Conference
    Apr 23 Day One wins FDA nod for brain cancer therapy, Ojemda
    Apr 15 Viracta slides on lower response rate in trial for lymphoma treatment cohort
    Apr 15 Viracta Therapeutics Announces Positive Topline Nana-val Results from Stage 1 of the NAVAL-1 Trial in Patients with Relapsed or Refractory Epstein-Barr Virus-Positive (EBV+) Peripheral T-Cell Lymphoma
    Mar 7 Viracta Therapeutics GAAP EPS of -$0.35 misses by $0.04
    Mar 7 Viracta Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
    Feb 29 Viracta Therapeutics Announces Completion of Second-Stage Enrollment into the Peripheral T-Cell Lymphoma Cohort of the NAVAL-1 Trial
    See more VIRX news...

    Comments

    View full discussion...

    Indicators

    Indicator Value
    52 Week High 1.67
    52 Week Low 0.43
    Average Volume 81,225
    200-Day Moving Average 0.73
    50-Day Moving Average 0.72
    20-Day Moving Average 0.60
    10-Day Moving Average 0.58
    Average True Range 0.07
    RSI (14) 35.90
    ADX 18.69
    +DI 15.35
    -DI 19.32
    Chandelier Exit (Long, 3 ATRs) 0.60
    Chandelier Exit (Short, 3 ATRs) 0.72
    Upper Bollinger Bands 0.71
    Lower Bollinger Band 0.50
    Percent B (%b) 0.06
    BandWidth 34.70
    MACD Line -0.05
    MACD Signal Line -0.05
    MACD Histogram -0.0022
    Fundamentals Value
    Market Cap 19.7 Million
    Num Shares 38.6 Million
    EPS -1.24
    Price-to-Earnings (P/E) Ratio -0.41
    Price-to-Sales 0.00
    Price-to-Book 0.88
    Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
    Resistance 4 (R4) 0.60
    Resistance 3 (R3) 0.61 0.59 0.58
    Resistance 2 (R2) 0.59 0.57 0.58 0.58
    Resistance 1 (R1) 0.55 0.55 0.54 0.54 0.57
    Pivot Point 0.53 0.53 0.52 0.52 0.53
    Support 1 (S1) 0.49 0.51 0.48 0.48 0.45
    Support 2 (S2) 0.47 0.49 0.47 0.44
    Support 3 (S3) 0.43 0.47 0.44
    Support 4 (S4) 0.42